{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Refractory+Renal+Cell+Carcinoma&page=3", "query": { "condition": "Refractory Renal Cell Carcinoma", "page": 3 }, "page_size": 10 }, "pagination": { "page": 3, "page_size": 10, "total_count": 140, "total_pages": 14, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Refractory+Renal+Cell+Carcinoma&page=4&page_size=10", "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Refractory+Renal+Cell+Carcinoma&page=2&page_size=10" }, "source": "remote", "last_synced_at": "2026-10-05T07:58:07.554Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT00617929", "title": "Antithymocyte Globulin, Clofarabine, and Rituximab in Treating Patients After an Unsuccessful Stem Cell Transplant", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Cancer" ], "interventions": [ { "name": "anti-thymocyte globulin", "type": "BIOLOGICAL" }, { "name": "rituximab", "type": "BIOLOGICAL" }, { "name": "clofarabine", "type": "DRUG" }, { "name": "stem cell transplantation", "type": "PROCEDURE" } ], "intervention_types": [ "BIOLOGICAL", "DRUG", "PROCEDURE" ], "sponsor": "Masonic Cancer Center, University of Minnesota", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": null, "maximum_age": null, "sex": "ALL", "summary": "Not listed" }, "enrollment_count": 12, "start_date": "2008-01", "completion_date": "2015-10", "has_results": true, "last_update_posted_date": "2017-12-28", "last_synced_at": "2026-10-05T07:58:07.554Z", "location_count": 1, "location_summary": "Minneapolis, Minnesota", "locations": [ { "city": "Minneapolis", "state": "Minnesota" } ], "official_url": "https://clinicaltrials.gov/study/NCT00617929" }, { "nct_id": "NCT00005045", "title": "Carboxyamidotriazole in Treating Patients With Advanced Kidney Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Kidney Cancer" ], "interventions": [ { "name": "carboxyamidotriazole", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Eastern Cooperative Oncology Group", "sponsor_class": "NETWORK", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": null, "start_date": "2000-03", "completion_date": "2004-06", "has_results": false, "last_update_posted_date": "2013-06-21", "last_synced_at": "2026-10-05T07:58:07.554Z", "location_count": 52, "location_summary": "Scottsdale, Arizona • Los Angeles, California • Palo Alto, California + 36 more", "locations": [ { "city": "Scottsdale", "state": "Arizona" }, { "city": "Los Angeles", "state": "California" }, { "city": "Palo Alto", "state": "California" }, { "city": "Stanford", "state": "California" }, { "city": "Denver", "state": "Colorado" } ], "official_url": "https://clinicaltrials.gov/study/NCT00005045" }, { "nct_id": "NCT00861107", "title": "In-Situ Therapeutic Cancer Vaccine for Metastatic Cancer Combining AlloStim With Tumor Cryoablation", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Metastatic Cancer" ], "interventions": [ { "name": "AlloStim-7", "type": "BIOLOGICAL" }, { "name": "percutaneous tumor cryoablation", "type": "PROCEDURE" }, { "name": "AlloStim8 or AlloStim-9", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL", "PROCEDURE" ], "sponsor": "Mirror Biologics, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 50, "start_date": "2009-08", "completion_date": "2011-05", "has_results": false, "last_update_posted_date": "2011-06-08", "last_synced_at": "2026-10-05T07:58:07.554Z", "location_count": 1, "location_summary": "Carlsbad, California", "locations": [ { "city": "Carlsbad", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT00861107" }, { "nct_id": "NCT00282048", "title": "Study Of AG-013736 In Patients With Refractory Metastatic Renal Cell Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Kidney Neoplasms", "Carcinoma, Renal Cell" ], "interventions": [ { "name": "AG-013736 (axitinib)", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Pfizer", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 62, "start_date": "2006-03", "completion_date": "2009-06", "has_results": true, "last_update_posted_date": "2012-07-31", "last_synced_at": "2026-10-05T07:58:07.554Z", "location_count": 5, "location_summary": "Chicago, Illinois • The Bronx, New York • Cleveland, Ohio + 2 more", "locations": [ { "city": "Chicago", "state": "Illinois" }, { "city": "The Bronx", "state": "New York" }, { "city": "Cleveland", "state": "Ohio" }, { "city": "Philadelphia", "state": "Pennsylvania" }, { "city": "Madison", "state": "Wisconsin" } ], "official_url": "https://clinicaltrials.gov/study/NCT00282048" }, { "nct_id": "NCT01762033", "title": "A Phase 2 Study of ASONEP™ to Treat Unresectable and Refractory Renal Cell Carcinoma", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Renal Cell Carcinoma" ], "interventions": [ { "name": "ASONEP", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Lpath, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 40, "start_date": "2013-02", "completion_date": "2015-09", "has_results": false, "last_update_posted_date": "2016-01-20", "last_synced_at": "2026-10-05T07:58:07.554Z", "location_count": 5, "location_summary": "Duarte, California • Fort Myers, Florida • Inverness, Florida + 2 more", "locations": [ { "city": "Duarte", "state": "California" }, { "city": "Fort Myers", "state": "Florida" }, { "city": "Inverness", "state": "Florida" }, { "city": "Charleston", "state": "South Carolina" }, { "city": "Nashville", "state": "Tennessee" } ], "official_url": "https://clinicaltrials.gov/study/NCT01762033" }, { "nct_id": "NCT01253668", "title": "Brivanib Metastatic Renal Cell Carcinoma", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Renal Cell Carcinoma" ], "interventions": [ { "name": "Brivanib alaninate", "type": "DRUG" }, { "name": "Polymerase chain reaction", "type": "GENETIC" }, { "name": "Iodine I 124 chimeric monoclonal antibody G250", "type": "OTHER" }, { "name": "Positron emission tomography/computed tomography", "type": "PROCEDURE" }, { "name": "Protein expression analysis", "type": "GENETIC" }, { "name": "Immunohistochemistry", "type": "OTHER" } ], "intervention_types": [ "DRUG", "GENETIC", "OTHER", "PROCEDURE" ], "sponsor": "Abramson Cancer Center at Penn Medicine", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 10, "start_date": "2011-11", "completion_date": "2013-09", "has_results": true, "last_update_posted_date": "2021-04-13", "last_synced_at": "2026-10-05T07:58:07.554Z", "location_count": 1, "location_summary": "Philadelphia, Pennsylvania", "locations": [ { "city": "Philadelphia", "state": "Pennsylvania" } ], "official_url": "https://clinicaltrials.gov/study/NCT01253668" }, { "nct_id": "NCT00890747", "title": "Sunitinib Malate in Treating HIV-Positive Patients With Cancer Receiving Antiretroviral Therapy", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Accelerated Phase Chronic Myelogenous Leukemia", "Acute Myeloid Leukemia With Multilineage Dysplasia Following Myelodysplastic Syndrome", "Acute Undifferentiated Leukemia", "Adult Acute Lymphoblastic Leukemia in Remission", "Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities", "Adult Acute Myeloid Leukemia With Del(5q)", "Adult Acute Myeloid Leukemia With Inv(16)(p13;q22)", "Adult Acute Myeloid Leukemia With t(15;17)(q22;q12)", "Adult Acute Myeloid Leukemia With t(16;16)(p13;q22)", "Adult Acute Myeloid Leukemia With t(8;21)(q22;q22)", "Adult Grade III Lymphomatoid Granulomatosis", "Adult Langerhans Cell Histiocytosis", "Adult Nasal Type Extranodal NK/T-cell Lymphoma", "Aggressive NK-cell Leukemia", "AIDS-related Diffuse Large Cell Lymphoma", "AIDS-related Diffuse Mixed Cell Lymphoma", "AIDS-related Diffuse Small Cleaved Cell Lymphoma", "AIDS-related Immunoblastic Large Cell Lymphoma", "AIDS-related Lymphoblastic Lymphoma", "AIDS-related Malignancies", "AIDS-related Small Noncleaved Cell Lymphoma", "Anaplastic Large Cell Lymphoma", "Angioimmunoblastic T-cell Lymphoma", "Atypical Chronic Myeloid Leukemia, BCR-ABL1 Negative", "Chronic Eosinophilic Leukemia", "Chronic Myelomonocytic Leukemia", "Chronic Neutrophilic Leukemia", "Chronic Phase Chronic Myelogenous Leukemia", "Clear Cell Renal Cell Carcinoma", "Cutaneous B-cell Non-Hodgkin Lymphoma", "de Novo Myelodysplastic Syndromes", "Essential Thrombocythemia", "Extramedullary Plasmacytoma", "Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue", "Hepatosplenic T-cell Lymphoma", "HIV Infection", "HIV-associated Hodgkin Lymphoma", "Intraocular Lymphoma", "Isolated Plasmacytoma of Bone", "Light Chain Deposition Disease", "Mast Cell Leukemia", "Myelodysplastic Syndrome With Isolated Del(5q)", "Myelodysplastic/Myeloproliferative Neoplasm, Unclassifiable", "Myeloid/NK-cell Acute Leukemia", "Nodal Marginal Zone B-cell Lymphoma", "Noncutaneous Extranodal Lymphoma", "Osteolytic Lesions of Multiple Myeloma", "Peripheral T-cell Lymphoma", "Plasma Cell Neoplasm", "Polycythemia Vera", "Post-transplant Lymphoproliferative Disorder", "Previously Treated Myelodysplastic Syndromes", "Primary Myelofibrosis", "Primary Systemic Amyloidosis", "Progressive Hairy Cell Leukemia, Initial Treatment", "Prolymphocytic Leukemia", "Recurrent Adult Acute Lymphoblastic Leukemia", "Recurrent Adult Acute Myeloid Leukemia", "Recurrent Adult Burkitt Lymphoma", "Recurrent Adult Diffuse Large Cell Lymphoma", "Recurrent Adult Diffuse Mixed Cell Lymphoma", "Recurrent Adult Diffuse Small Cleaved Cell Lymphoma", "Recurrent Adult Grade III Lymphomatoid Granulomatosis", "Recurrent Adult Hodgkin Lymphoma", "Recurrent Adult Immunoblastic Large Cell Lymphoma", "Recurrent Adult Lymphoblastic Lymphoma", "Recurrent Adult T-cell Leukemia/Lymphoma", "Recurrent Cutaneous T-cell Non-Hodgkin Lymphoma", "Recurrent Grade 1 Follicular Lymphoma", "Recurrent Grade 2 Follicular Lymphoma", "Recurrent Grade 3 Follicular Lymphoma", "Recurrent Mantle Cell Lymphoma", "Recurrent Marginal Zone Lymphoma", "Recurrent Mycosis Fungoides/Sezary Syndrome", "Recurrent Renal Cell Cancer", "Recurrent Small Lymphocytic Lymphoma", "Refractory Chronic Lymphocytic Leukemia", "Refractory Hairy Cell Leukemia", "Refractory Multiple Myeloma", "Relapsing Chronic Myelogenous Leukemia", "Stage IV Renal Cell Cancer", "T-cell Large Granular Lymphocyte Leukemia", "Testicular Lymphoma", "Unspecified Adult Solid Tumor, Protocol Specific", "Waldenström Macroglobulinemia" ], "interventions": [ { "name": "sunitinib malate", "type": "DRUG" }, { "name": "pharmacological study", "type": "OTHER" }, { "name": "laboratory biomarker analysis", "type": "OTHER" } ], "intervention_types": [ "DRUG", "OTHER" ], "sponsor": "National Cancer Institute (NCI)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 42, "start_date": "2009-08", "completion_date": null, "has_results": false, "last_update_posted_date": "2014-03-17", "last_synced_at": "2026-10-05T07:58:07.554Z", "location_count": 11, "location_summary": "Los Angeles, California • Washington D.C., District of Columbia • Chicago, Illinois + 8 more", "locations": [ { "city": "Los Angeles", "state": "California" }, { "city": "Washington D.C.", "state": "District of Columbia" }, { "city": "Chicago", "state": "Illinois" }, { "city": "Rockville", "state": "Maryland" }, { "city": "Boston", "state": "Massachusetts" } ], "official_url": "https://clinicaltrials.gov/study/NCT00890747" }, { "nct_id": "NCT01048892", "title": "Seneca Valley Virus-001 and Cyclophosphamide in Treating Young Patients With Relapsed or Refractory Neuroblastoma, Rhabdomyosarcoma, or Rare Tumors With Neuroendocrine Features", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Adrenocortical Carcinoma", "Gastrointestinal Carcinoid Tumor", "Kidney Cancer", "Neuroblastoma", "Retinoblastoma", "Sarcoma" ], "interventions": [ { "name": "Seneca Valley virus-001", "type": "BIOLOGICAL" }, { "name": "cyclophosphamide", "type": "DRUG" }, { "name": "laboratory biomarker analysis", "type": "OTHER" }, { "name": "pharmacological study", "type": "OTHER" } ], "intervention_types": [ "BIOLOGICAL", "DRUG", "OTHER" ], "sponsor": "Children's Oncology Group", "sponsor_class": "NETWORK", "healthy_volunteers": false, "eligibility": { "minimum_age": "3 Years", "maximum_age": "21 Years", "sex": "ALL", "summary": "3 Years to 21 Years" }, "enrollment_count": 22, "start_date": "2009-09", "completion_date": null, "has_results": false, "last_update_posted_date": "2014-01-30", "last_synced_at": "2026-10-05T07:58:07.554Z", "location_count": 18, "location_summary": "Birmingham, Alabama • Orange, California • San Francisco, California + 15 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Orange", "state": "California" }, { "city": "San Francisco", "state": "California" }, { "city": "Washington D.C.", "state": "District of Columbia" }, { "city": "Chicago", "state": "Illinois" } ], "official_url": "https://clinicaltrials.gov/study/NCT01048892" }, { "nct_id": "NCT00003408", "title": "Biological Therapy Following Chemotherapy and Peripheral Stem Cell Transplantation in Treating Patients With Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Breast Cancer", "Chronic Myeloproliferative Disorders", "Gestational Trophoblastic Tumor", "Kidney Cancer", "Leukemia", "Lymphoma", "Multiple Myeloma and Plasma Cell Neoplasm", "Myelodysplastic Syndromes", "Neuroblastoma", "Ovarian Cancer", "Sarcoma", "Testicular Germ Cell Tumor" ], "interventions": [ { "name": "aldesleukin", "type": "BIOLOGICAL" }, { "name": "recombinant interferon alfa", "type": "BIOLOGICAL" }, { "name": "sargramostim", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL" ], "sponsor": "Cancer Treatment Centers of America", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": null, "maximum_age": null, "sex": "ALL", "summary": "Not listed" }, "enrollment_count": 40, "start_date": "1998-04", "completion_date": "2000-03", "has_results": false, "last_update_posted_date": "2013-03-26", "last_synced_at": "2026-10-05T07:58:07.554Z", "location_count": 1, "location_summary": "Zion, Illinois", "locations": [ { "city": "Zion", "state": "Illinois" } ], "official_url": "https://clinicaltrials.gov/study/NCT00003408" }, { "nct_id": "NCT00002673", "title": "Immunotherapy in Treating Patients Who Are Undergoing Bone Marrow or Peripheral Stem Cell Transplantation", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Cancer" ], "interventions": [ { "name": "infection prophylaxis and management", "type": "PROCEDURE" } ], "intervention_types": [ "PROCEDURE" ], "sponsor": "Fred Hutchinson Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "12 Years", "maximum_age": "60 Years", "sex": "ALL", "summary": "12 Years to 60 Years" }, "enrollment_count": 30, "start_date": "1995-06", "completion_date": "2002-02", "has_results": false, "last_update_posted_date": "2010-06-17", "last_synced_at": "2026-10-05T07:58:07.554Z", "location_count": 1, "location_summary": "Seattle, Washington", "locations": [ { "city": "Seattle", "state": "Washington" } ], "official_url": "https://clinicaltrials.gov/study/NCT00002673" } ] }